survodutide vs Zabopegdutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/glucagon receptor (dual) · full Obesity pipeline
survodutide
Developed by Boehringer Ingelheim under a licence from Zealand Pharma
NCT06077864 · Phase 3 · completed
The study randomly assigns 5,531 participants to two survodutide doses or placebo and uses quadruple blinding. Its primary endpoint is a hard clinical composite of cardiovascular death, nonfatal stroke, nonfatal heart attack, coronary revascularization, or heart-failure events, but the non-inferiority result is not yet available.
Next expected readout: December 2026 · NCT07768813 (registry estimate)
Reported efficacy
Percentage change in body weight from baseline to Week 76 (Baseline and at Week 76); Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76 (Baseline and at Week 76): Percentage change in body weight from baseline to Week 76 (SYNCHRONIZE-1, primary analysis, treatment-regimen estimand): -13.0% survodutide 6.0 mg and -12.2% 3.6 mg vs -5.4% placebo; body weight reduction of at least 5%: 71.9% and 72.6% vs 46.3% (P<0.001 for all comparisons with placebo). (met)
Result source: NCT06066515
Zabopegdutide
Developed by D&D Pharmatech and partners
NCT04812262 · Phase 1 · completed
This Phase 1 study randomized overweight or obese adults with type 2 diabetes and fatty liver disease to DD01 or placebo in sequential single and multiple ascending-dose cohorts, with quadruple blinding and 255 participants in total. All of its registered primary endpoints measured safety and tolerability, so the trial made no formal efficacy test, and no results were posted on the registry. The sponsor announced a reduction in liver fat measured by MRI-PDFF in the high-dose group (p < 0.0001 versus placebo), but that outcome was not a registered primary endpoint and the figure comes from a company press release.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported efficacy
Number of participants with treatment-related adverse events and serious adverse events (Part A - 43 days); Number of participants with treatment-related adverse events and serious adverse events (TEAEs) (Part B - 57 days); Number of participants with clinically significant abnormalities in clinical laboratory values (Part A - 43 days); Number of participants with clinically significant abnormalities in clinical laboratory values (Part B - 57 days); Number of participants with clinically significant abnormalities in physical examinations (Part A - 43 days); Number of participants with clinically significant abnormalities in physical examinations (Part B - 57 days); Number of participants with clinically significant abnormalities in vital signs (Part A - 43 days); Number of participants with clinically significant abnormalities in vital signs (Part B - 57 days); Blood Pressure assessed by 24-hour ambulatory blood pressure monitoring (ABPM) (Part A - 43 days); Blood Pressure assessed by 24-hour ambulatory blood pressure monitoring (ABPM) (Part B - 57 days); Heart Rate assessed by 24-hour ambulatory electrocardiography monitoring reader) (Part A - 43 days); Heart Rate assessed by 24-hour ambulatory electrocardiography monitoring reader) (Part B - 57 days); Number of participants with clinically significant abnormalities in 12-lead ECGs (Part A - 43 days); Number of participants with clinically significant abnormalities in 12-lead ECGs (Part B - 57 days): Randomized, double-blind, placebo-controlled single and multiple ascending dose study at four US clinical sites: following only 4 weeks of treatment, all subjects in the high dose group achieved at least a 40% reduction in liver fat, with a mean reduction of more than 50% measured by MRI-PDFF (p < 0.0001 versus placebo). (not_applicable)
Result source: NCT04812262
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | survodutide | Zabopegdutide |
|---|---|---|
| Body weight, % change | -14.9% vs -2.8%−12.1 vs placeboNCT046673774 other results
| —Not reported |
| Weight loss of 5% or more | 82.8% vs 25.9%+56.9 vs placeboNCT046673773 other results
| —Not reported |
| Weight loss of 10% or more | 68.8% vs 11.1%+57.7 vs placeboNCT046673773 other results
| —Not reported |
| Waist circumference, change (cm) | -16.0 vs -4.0−12 vs placeboNCT046673773 other results
| —Not reported |
Body weight, % change
- survodutide
- -14.9% vs -2.8%−12.1 vs placeboNCT04667377
4 other results
- -13.2% vs -2.8% NCT04667377
- -12.5% vs -2.8% NCT04667377
- -6.2% vs -2.8% NCT04667377
- -16.6% vs -3.2% NCT06066515
- Zabopegdutide
- —Not reported
Weight loss of 5% or more
- survodutide
- 82.8% vs 25.9%+56.9 vs placeboNCT04667377
3 other results
- 82% vs 25.9% NCT04667377
- 81% vs 25.9% NCT04667377
- 60.7% vs 25.9% NCT04667377
- Zabopegdutide
- —Not reported
Weight loss of 10% or more
- survodutide
- 68.8% vs 11.1%+57.7 vs placeboNCT04667377
3 other results
- 65.6% vs 11.1% NCT04667377
- 65.5% vs 11.1% NCT04667377
- 33.9% vs 11.1% NCT04667377
- Zabopegdutide
- —Not reported
Waist circumference, change (cm)
- survodutide
- -16.0 vs -4.0−12 vs placeboNCT04667377
3 other results
- -15.0 vs -4.0 NCT04667377
- -15.0 vs -4.0 NCT04667377
- -8.3 vs -4.0 NCT04667377
- Zabopegdutide
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Zabopegdutide: no structured comparison results are available for Obesity.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. survodutide: 4 of 4 rows · Zabopegdutide: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | survodutide |
|---|---|
| Dropout rate | —4.8 mga NCT04667377 · Phase 2 · registry result, not featured evidence show 7 more results28.6%4.8 mg NCT04667377 · Phase 2 · registry result, not featured evidence —3.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence 23.4%3.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence —2.4 mg NCT04667377 · Phase 2 · registry result, not featured evidence 23.1%2.4 mg NCT04667377 · Phase 2 · registry result, not featured evidence —0.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence 29.5%0.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —4.8 mga NCT04667377 · Phase 2 · registry result, not featured evidence show 7 more results23.4%4.8 mg NCT04667377 · Phase 2 · registry result, not featured evidence —3.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence 18.2%3.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence —2.4 mg NCT04667377 · Phase 2 · registry result, not featured evidence 14.1%2.4 mg NCT04667377 · Phase 2 · registry result, not featured evidence —0.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence 16.7%0.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 7.4%4.8 mga NCT04667377 · Phase 2 · registry result, not featured evidence show 7 more results—4.8 mg NCT04667377 · Phase 2 · registry result, not featured evidence 5.6%3.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence —3.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence 3.3%2.4 mg NCT04667377 · Phase 2 · registry result, not featured evidence —2.4 mg NCT04667377 · Phase 2 · registry result, not featured evidence 2.2%0.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence —0.6 mg NCT04667377 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 4.8 mga nausea 59.3% (placebo 19.5%) constipation 24.1% (placebo 5.2%) vomiting 24.1% (placebo 5.2%) NCT04667377 · Phase 2 · registry result, not featured evidence show 3 more results3.6 mg nausea 63.4% (placebo 19.5%) vomiting 39.4% (placebo 5.2%) constipation 31% (placebo 5.2%) NCT04667377 · Phase 2 · registry result, not featured evidence 2.4 mg nausea 65.2% (placebo 19.5%) vomiting 30.4% (placebo 5.2%) diarrhoea 22.8% (placebo 10.4%) NCT04667377 · Phase 2 · registry result, not featured evidence 0.6 mg nausea 39.1% (placebo 19.5%) diarrhoea 23.9% (placebo 10.4%) covid-19 19.6% (placebo 22.1%) NCT04667377 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
survodutide
show 4 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
MASH / NASH
Shared mechanism: GLP-1/glucagon receptor (dual) · full MASH / NASH pipeline
survodutide
Developed by Boehringer Ingelheim under a licence from Zealand Pharma
NCT06309992 · Phase 3 · completed
This phase 3 trial randomly assigned 216 adults with obesity and at-risk MASLD (2:1) to weekly survodutide 6.0 mg or placebo, with double-blind treatment for 48 weeks. The first co-primary endpoint was a reduction of at least 30% in liver fat on MRI: 84.2% of survodutide patients reached it against 24.3% on placebo (P<0.0001). The second co-primary endpoint was body weight change: -12.2% against -1.0% (P<0.0001). Both co-primary endpoints were met, so the result is met. The figures come from the peer-reviewed Nature Medicine paper.
Next expected readout: April 2029 · NCT07850063 (registry estimate)
Reported efficacy
Relative reduction in liver fat content of at least 30% from baseline to Week 48 (yes/no) assessed by magnetic resonance imaging proton density fat fraction (MRI-PDFF) [%] (at baseline, at week 48); Relative change (%) in body weight [kg] from baseline to Week 48 (at baseline, at week 48): Co-primary 1, ≥30% reduction in MRI-PDFF liver fat content at week 48: 84.2% survodutide 6.0 mg vs 24.3% placebo (efficacy estimand, P<0.0001; treatment regimen estimand 68.5% vs 28.6%, P<0.0001), met. Co-primary 2, percentage change in body weight at week 48: -12.2% vs -1.0% (efficacy estimand, P<0.0001; treatment regimen estimand -8.7% vs -1.4%, P<0.0001), met. (met)
Result source: NCT06309992
Zabopegdutide
Developed by D&D Pharmatech and partners
NCT06410924 · Phase 2 · completed
This randomized, triple-blind, placebo-controlled Phase 2 trial enrolled 67 people with fatty liver disease and measured the proportion who achieved at least a 30% reduction in liver fat, measured by MRI scan, after 12 weeks. DD01 met this imaging-based endpoint far more often than placebo (75.8% vs 11.8%), though liver-fat reduction on imaging is an earlier marker of benefit rather than the biopsy-confirmed liver-disease improvement that later-stage trials assess.
Reported efficacy
Proportion of subjects who achieve at least 30% liver fat reduction measured by MRI-PDFF (12 weeks): Proportion of subjects achieving at least 30% liver fat reduction by MRI-PDFF at 12 weeks: 75.8% (DD01) vs 11.8% (placebo); p<0.0001. (met)
Result source: NCT06410924
Results for MASH / NASH
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | survodutide | Zabopegdutide |
|---|---|---|
| MASH resolution without fibrosis worsening | —Not posted · NCT06309992 | —Not reported |
| Fibrosis stage, change | —Not posted · NCT06309992 | —Not reported |
| Liver fat (MRI-PDFF), change | -13.0% vs -1.9%−11.1 vs placeboNCT0477127311 other results
| —Not reported |
| ALT, change | —Not posted · NCT06309992 | —Not reported |
MASH resolution without fibrosis worsening
- survodutide
- —Not posted · NCT06309992
- Zabopegdutide
- —Not reported
Fibrosis stage, change
- survodutide
- —Not posted · NCT06309992
- Zabopegdutide
- —Not reported
Liver fat (MRI-PDFF), change
- survodutide
- -13.0% vs -1.9%−11.1 vs placeboNCT04771273
11 other results
- -12.5% vs -1.6% NCT04771273
- -64.3% vs -7.3% NCT04771273
- -62.0% vs -5.7% NCT04771273
- -12.8% vs -1.9% NCT04771273
- -12.4% vs -1.6% NCT04771273
- -62.8% vs -7.3% NCT04771273
- -60.8% vs -5.7% NCT04771273
- -10.5% vs -1.9% NCT04771273
- -10.7% vs -1.6% NCT04771273
- -50.9% vs -7.3% NCT04771273
- -52.2% vs -5.7% NCT04771273
- Zabopegdutide
- —Not reported
ALT, change
- survodutide
- —Not posted · NCT06309992
- Zabopegdutide
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. survodutide: 5 of 5 rows · Zabopegdutide: 1 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | survodutide | Zabopegdutide |
|---|---|---|
| MRI-PDFF ≥30% responder rate · % of participants | 76.9% (n=52) vs 16.5% (n=79) placebo @ 48wk6.0 mga,b,c,d NCT04771273 · Phase 2 · registry result, not featured evidence show 5 more doses56.8% (n=74) vs 13.5% (n=74) placebo @ 48wk6.0 mg NCT04771273 · Phase 2 · registry result, not featured evidence 66.7% (n=69) vs 16.5% (n=79) placebo @ 48wk4.8 mg NCT04771273 · Phase 2 · registry result, not featured evidence 66.7% (n=72) vs 13.5% (n=74) placebo @ 48wk4.8 mg NCT04771273 · Phase 2 · registry result, not featured evidence 50.5% (n=93) vs 16.5% (n=79) placebo @ 48wk2.4 mg NCT04771273 · Phase 2 · registry result, not featured evidence 63% (n=73) vs 13.5% (n=74) placebo @ 48wk2.4 mg NCT04771273 · Phase 2 · registry result, not featured evidence | 75.8% vs 11.8% placebo @ 12wkb,c,d NCT06410924 · Phase 2 · sponsor-reported, not registry data |
| Dropout rate | —6.0 mge NCT04771273 · Phase 2 · registry result, not featured evidence show 5 more results24%6.0 mg NCT04771273 · Phase 2 · registry result, not featured evidence —4.8 mg NCT04771273 · Phase 2 · registry result, not featured evidence 13.7%4.8 mg NCT04771273 · Phase 2 · registry result, not featured evidence —2.4 mg NCT04771273 · Phase 2 · registry result, not featured evidence 15.1%2.4 mg NCT04771273 · Phase 2 · registry result, not featured evidence | — |
| Discontinued due to AEs | —6.0 mge NCT04771273 · Phase 2 · registry result, not featured evidence show 5 more results16%6.0 mg NCT04771273 · Phase 2 · registry result, not featured evidence —4.8 mg NCT04771273 · Phase 2 · registry result, not featured evidence 12.3%4.8 mg NCT04771273 · Phase 2 · registry result, not featured evidence —2.4 mg NCT04771273 · Phase 2 · registry result, not featured evidence 11%2.4 mg NCT04771273 · Phase 2 · registry result, not featured evidence | — |
| Serious AEs | 9.6%6.0 mge NCT04771273 · Phase 2 · registry result, not featured evidence show 5 more results—6.0 mg NCT04771273 · Phase 2 · registry result, not featured evidence 10.1%4.8 mg NCT04771273 · Phase 2 · registry result, not featured evidence —4.8 mg NCT04771273 · Phase 2 · registry result, not featured evidence 5.4%2.4 mg NCT04771273 · Phase 2 · registry result, not featured evidence —2.4 mg NCT04771273 · Phase 2 · registry result, not featured evidence | — |
| Most frequent reported AEs | 6.0 mge nausea 63.5% (placebo 27.8%) diarrhoea 55.8% (placebo 25.3%) constipation 28.8% (placebo 17.7%) NCT04771273 · Phase 2 · registry result, not featured evidence show 2 more results4.8 mg nausea 66.7% (placebo 27.8%) diarrhoea 53.6% (placebo 25.3%) vomiting 47.8% (placebo 7.6%) NCT04771273 · Phase 2 · registry result, not featured evidence 2.4 mg nausea 64.5% (placebo 27.8%) diarrhoea 40.9% (placebo 25.3%) vomiting 40.9% (placebo 7.6%) NCT04771273 · Phase 2 · registry result, not featured evidence | — |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation context differs: registered conditions differ.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 48 weeks versus 12 weeks.
- ePopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
survodutide
show 5 more results
show 11 more results
show 5 more results
show 5 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: survodutide's landscape · Zabopegdutide's landscape